Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
There are currently no disease-modifying therapeutics for Parkinson’s disease (PD). Although extensive efforts were undertaken to develop therapeutic approaches to delay the symptoms of PD, untreated α-synucle...